KYTX
Kyverna Therapeutics, Inc. Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$527.09M
P/E Ratio
—
EPS
$-3.27
Beta
2.06
52W High
$13.67
52W Low
$2.43
50-Day MA
$9.06
200-Day MA
$7.45
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Kyverna Therapeutics, Inc. Common Stock
Kyverna Therapeutics, Inc. is an innovative biotechnology company focused on developing cutting-edge immunotherapies for autoimmune diseases and other serious medical conditions. Utilizing its proprietary genetically engineered T-cell technology, Kyverna aims to enhance immune system functionality, offering specialized therapeutic solutions that promise better disease management outcomes. With a strategic emphasis on cellular therapies, the company is well-positioned to capitalize on the growing biopharmaceutical sector, presenting significant opportunities for institutional investors interested in cutting-edge treatments and the expanding immunotherapy landscape.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | $-126.36M |
| EBITDA | $-162.14M |
| Operating Margin | 0.00% |
| Return on Equity | -74.60% |
| Return on Assets | -39.60% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $3.23 |
| Price-to-Book | 2.69 |
| Price-to-Sales (TTM) | 3513.34 |
| EV/Revenue | 3341.48 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $60.80M |
| Float | $35.50M |
| % Insiders | 7.07% |
| % Institutions | 74.06% |
Historical Volatility
HV 10-Day
107.86%
HV 20-Day
80.20%
HV 30-Day
98.68%
HV 60-Day
87.93%
HV Rank
42.1%
Volatility is currently expanding
Analyst Ratings
Consensus ($30.40 target)
2
Strong Buy4
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026